Oral and Poster Abstracts
Poster
Adult, ALL, apoptosis, Biological, Leukemia, multiple myeloma, CLL, Diseases, drug-drug interaction, Lymphoma (any), Non-Biological, biopsy, cell regulation, Combinations, Mantle Cell Lymphoma, Therapies, chemotherapy, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Biological Processes, blood product storage, DLBCL, Technology and Procedures, Cell Lineage, epigenetics, Plasma Cell Disorders, Xenograft models, Lymphoid Malignancies, Study Population, Clinically relevant, genetic profiling, genomics, imaging, flow cytometry, molecular testing, NGS, molecular interactions, RNA sequencing, pathogenesis, pathways, proteomics, signal transduction
Ryosuke Shirasaki, MD, PhD1,2*, Esperanza M Algarín, PhD1*, Ricardo De Matos Simoes, PhD1,2*, Sondra L. Downey-Kopyscinski, PhD1,2*, Shizuka Yamano1,2*, Xiaolin Luo3*, Youngsoo Kim, PhD3*, Robert MacLeod3* and Constantine S. Mitsiades, MD, PhD2,4
1Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
2Broad Institute of MIT and Harvard, Cambridge, MA
3Ionis Pharmaceuticals, Inc., Carlsbad, CA
4Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Brookline, MA
Jiarui Liu1,2*, Xiangxiang Zhou, MD1,2*, Ya Zhang, MD1,3*, Shunfeng Hu, MM1,3*, Yang Han, MM1,3*, Juan Yang, PhD1,3*, Yi Zhao, MM1,3*, Shuai Ren, MM1,3*, Yiqing Cai1,3* and Xin Wang, MD, PhD1,3
1Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China
2Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
3Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
Michelle Wang, BSE1*, Xiaohong Zhao, MD, PhD1*, Huijuan Jiang, MD2*, Joy Catherine Yan1*, Eduardo Sotomayor, MD3, Kenneth H. Shain, MD, PhD 4, Bijal Shah, MD1 and Jianguo Tao, MD, PhD1
1Moffitt Cancer Center, Tampa, FL
2Tianjin Medical School, Tianjin, China
3George Washington University Cancer Center, Washington, DC
4Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Saint Petersburg, FL
Stephen Jun Fei Chong*, Mary C Collins, BS*, Liam Hackett, BS* and Matthew S. Davids, MD
Dana-Farber Cancer Institute, Boston, MA
Sara M.A. Mohamed1,2*, Keith Sia, PhD2*, Karl-Heinz Friedrich, PhD3*, Andreas Wohlmann, Dr3*, Savvas Savvides, PhD4*, Peter Schofield, PhD5*, Daniel Christ, PhD5,6*, Maria Kavallaris, PhD2,7*, Richard B. Lock, PhD8 and Narges Bayat, PhD2*
1Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
2Children's Cancer Institute, School of Women’s and Children’s Health, UNSW Sydney, Sydney, NSW, Australia
3Institute of Biochemistry II, Jena University Hospital, Jena, Germany
4VIB-UGent Centre for Inflammation Research, Gent, Belgium
5Garvan Institute of Medical Research, Sydney, NSW, Australia
6St. Vincent’s Clinical School, Faculty of Medicine, UNSW Sydney, Sydeny, Australia
7Australian Centre for Nanomedicine, ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, UNSW Sydney, Sydney, Australia
8Children's Cancer Inst. Australia Lowy Cancer Research Centre, Univ N.S.W., Randwick, NSW, Australia
Konstantin Byrgazov, PhD1*, Marianne Kraus2*, Andrej Besse2*, Ana Slipicevic1*, Fredrik Lehmann1*, Christoph Driessen, MD2 and Lenka Besse2*
1Oncopeptides AB, Stockholm, Sweden
2Department of Oncology and Hematology, Laboratory of Experimental Oncology, St. Gallen Cantonal Hospital, St. Gallen, Switzerland
Maria Cosenza, MS*, Stefano Sacchi, MD and Samantha Pozzi, MD
Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia, Modena, Italy
*signifies non-member of ASH
denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.